A major breakthrough for the field of RNA therapeutics Avidity Biosciences announced today that its investigational treatment for myotonic dystrophy type 1 (DM1), called AOC 1001, can be delivered into… Read More »
Promising findings from Avidity’s myotonic dystrophy trial
Springboards to the future
Everything we do propels us faster toward treatments and a cure We often speak of “filling potholes” and “overcoming obstacles” toward treatments and cures, but what the FSHD Society has… Read More »
Using our leverage
A few years ago, we told our donors that a gift to the FSHD Society “is one of the most powerful investments you will ever make to advance medical research.”… Read More »
$3.4 million to speed us on our journey (Part 3)
The foundations on which drug development happens “Infrastructure is basic physical and organizational structures…needed for the operation of a society or enterprise.” —Oxford Dictionary In a rare condition like FSHD, it’s… Read More »
$3.4 million to speed us on our journey (Part 2)
Building tools to accelerate drug development and clinical trials In the pioneering days of the Society, all our research funding went to basic research aimed at discovering the genetic cause… Read More »